| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Prevention of HIV-1 infection with early antiretroviral therapy.
|
N Engl J Med
|
2011
|
69.36
|
|
2
|
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
|
AIDS
|
2005
|
4.07
|
|
3
|
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial.
|
J Infect Dis
|
2011
|
3.78
|
|
4
|
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
|
Lancet
|
2013
|
3.57
|
|
5
|
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
|
Lancet
|
2007
|
3.51
|
|
6
|
What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)?
|
PLoS One
|
2012
|
2.97
|
|
7
|
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
|
Lancet
|
2011
|
2.48
|
|
8
|
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
|
PLoS Med
|
2012
|
2.40
|
|
9
|
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
|
AIDS
|
2006
|
1.98
|
|
10
|
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052).
|
J Infect Dis
|
2013
|
1.77
|
|
11
|
Cost-effectiveness of genotype testing for primary resistance in Brazil.
|
J Acquir Immune Defic Syndr
|
2015
|
1.73
|
|
12
|
Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
|
AIDS
|
2007
|
1.73
|
|
13
|
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
|
N Engl J Med
|
2012
|
1.63
|
|
14
|
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
|
J Acquir Immune Defic Syndr
|
2012
|
1.53
|
|
15
|
Breast cancer in a cohort of human immunodeficiency virus (HIV)-infected women from Rio de Janeiro, Brazil: a cases series report and an incidence rate estimate.
|
Braz J Infect Dis
|
2011
|
1.44
|
|
16
|
The DART trial: 'The doctor's dilemma' revisited.
|
J Antimicrob Chemother
|
2011
|
1.42
|
|
17
|
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
|
Clin Infect Dis
|
2006
|
1.35
|
|
18
|
Sepsis is a major determinant of outcome in critically ill HIV/AIDS patients.
|
Crit Care
|
2010
|
1.30
|
|
19
|
Epidemiology of HIV in Latin America and the Caribbean.
|
Curr Opin HIV AIDS
|
2014
|
1.24
|
|
20
|
Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
|
AIDS
|
2011
|
1.19
|
|
21
|
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
|
J Acquir Immune Defic Syndr
|
2010
|
1.17
|
|
22
|
Survival of AIDS patients using two case definitions, Rio de Janeiro, Brazil, 1986-2003.
|
AIDS
|
2005
|
1.16
|
|
23
|
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
|
Antivir Ther
|
2009
|
1.15
|
|
24
|
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
|
AIDS
|
2010
|
1.15
|
|
25
|
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.
|
J Acquir Immune Defic Syndr
|
2007
|
1.12
|
|
26
|
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
|
Clin Infect Dis
|
2013
|
1.11
|
|
27
|
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
|
Antivir Ther
|
2010
|
1.10
|
|
28
|
Overcoming biological, behavioral, and structural vulnerabilities: new directions in research to decrease HIV transmission in men who have sex with men.
|
J Acquir Immune Defic Syndr
|
2013
|
1.07
|
|
29
|
Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
|
AIDS Res Hum Retroviruses
|
2011
|
1.06
|
|
30
|
Immune status at presentation for HIV clinical care in Rio de Janeiro and Baltimore.
|
J Acquir Immune Defic Syndr
|
2011
|
1.04
|
|
31
|
Distribution of immune cell subsets and cytokine-producing cells in the uterine cervix of human papillomavirus (HPV)-infected women: influence of HIV-1 coinfection.
|
Diagn Mol Pathol
|
2005
|
1.04
|
|
32
|
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.
|
AIDS
|
2012
|
1.03
|
|
33
|
Diagnostic detection of human immunodeficiency virus type 1 antibodies in urine: a brazilian study.
|
J Clin Microbiol
|
2002
|
1.01
|
|
34
|
Adherence to Early Antiretroviral Therapy: Results From HPTN 052, a Phase III, Multinational Randomized Trial of ART to Prevent HIV-1 Sexual Transmission in Serodiscordant Couples.
|
J Acquir Immune Defic Syndr
|
2015
|
1.01
|
|
35
|
Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil.
|
AIDS Res Hum Retroviruses
|
2010
|
1.01
|
|
36
|
HIV testing among pregnant women in Brazil: rates and predictors.
|
Rev Saude Publica
|
2008
|
1.00
|
|
37
|
Aging with HIV: an overview of an urban cohort in Rio de Janeiro (Brazil) across decades of life.
|
Braz J Infect Dis
|
2013
|
0.98
|
|
38
|
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
|
Clin Infect Dis
|
2004
|
0.97
|
|
39
|
Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.
|
BMC Infect Dis
|
2010
|
0.96
|
|
40
|
Seroprevalence and factors associated with herpes simplex virus type 2 among HIV-negative high-risk men who have sex with men from Rio de Janeiro, Brazil: a cross-sectional study.
|
BMC Infect Dis
|
2009
|
0.96
|
|
41
|
Acceptability of self-conducted home-based HIV testing among men who have sex with men in Brazil: data from an on-line survey.
|
Cad Saude Publica
|
2014
|
0.95
|
|
42
|
High levels of T lymphocyte activation in Leishmania-HIV-1 co-infected individuals despite low HIV viral load.
|
BMC Infect Dis
|
2010
|
0.95
|
|
43
|
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
|
AIDS
|
2005
|
0.95
|
|
44
|
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.
|
J Clin Microbiol
|
2014
|
0.95
|
|
45
|
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
|
J Acquir Immune Defic Syndr
|
2009
|
0.93
|
|
46
|
Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
|
J Med Virol
|
2009
|
0.92
|
|
47
|
Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997-2011.
|
BMC Infect Dis
|
2014
|
0.92
|
|
48
|
Microbial translocation induces an intense proinflammatory response in patients with visceral leishmaniasis and HIV type 1 coinfection.
|
J Infect Dis
|
2013
|
0.91
|
|
49
|
Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
|
Int J Cancer
|
2011
|
0.91
|
|
50
|
Anal human papillomavirus (HPV) prevalences and factors associated with abnormal anal cytology in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil.
|
AIDS Patient Care STDS
|
2015
|
0.90
|
|
51
|
Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities.
|
AIDS Behav
|
2012
|
0.90
|
|
52
|
Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV co-infection: comparative study by tissue micro-array (TMA).
|
BMC Cancer
|
2008
|
0.90
|
|
53
|
Factors associated with colposcopy-histopathology confirmed cervical intraepithelial neoplasia among HIV-infected women from Rio De Janeiro, Brazil.
|
PLoS One
|
2011
|
0.87
|
|
54
|
Anal HPV prevalence and associated factors among HIV-seropositive men under antiretroviral treatment in Brazil.
|
J Acquir Immune Defic Syndr
|
2011
|
0.87
|
|
55
|
Syphilis in HIV-infected mothers and infants: results from the NICHD/HPTN 040 study.
|
Pediatr Infect Dis J
|
2015
|
0.87
|
|
56
|
Occult hepatitis B virus infection in HIV-infected patients: Evaluation of biochemical, virological and molecular parameters.
|
Hepatol Res
|
2008
|
0.87
|
|
57
|
Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.
|
J Acquir Immune Defic Syndr
|
2017
|
0.87
|
|
58
|
HIV rapid testing as a key strategy for prevention of mother-to-child transmission in Brazil.
|
Rev Saude Publica
|
2010
|
0.86
|
|
59
|
Behavior surveillance: prevalence and factors associated with high-risk sexual behavior among HIV-infected men in Brazil in the post-HAART era.
|
AIDS Behav
|
2008
|
0.86
|
|
60
|
Randomized clinical trial comparing the pharmacokinetics of standard- and increased-dosage lopinavir-ritonavir coformulation tablets in HIV-positive pregnant women.
|
Antimicrob Agents Chemother
|
2014
|
0.85
|
|
61
|
Participation of women in HIV clinical trials: the IPEC-FIOCRUZ experience.
|
HIV AIDS (Auckl)
|
2011
|
0.85
|
|
62
|
Maternal outcomes after HAART for the prevention of mother-to-child transmission in HIV-infected women in Brazil.
|
Antivir Ther
|
2011
|
0.85
|
|
63
|
Phylogenetic analysis of Brazilian HIV type 1 subtype D strains: tracing the origin of this subtype in Brazil.
|
AIDS Res Hum Retroviruses
|
2006
|
0.84
|
|
64
|
Pregnancy rates and predictors in women with HIV/AIDS in Rio de Janeiro, Southeastern Brazil.
|
Rev Saude Publica
|
2011
|
0.84
|
|
65
|
The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods.
|
BMC Public Health
|
2014
|
0.84
|
|
66
|
The innate immune response in HIV/AIDS septic shock patients: a comparative study.
|
PLoS One
|
2013
|
0.83
|
|
67
|
Plasma viral load threshold for sustaining intrahost HIV type 1 evolution.
|
AIDS Res Hum Retroviruses
|
2007
|
0.83
|
|
68
|
Incidence and determinants of severe morbidity among HIV-infected patients from Rio de Janeiro, Brazil, 2000-2010.
|
Antivir Ther
|
2014
|
0.83
|
|
69
|
Recurrence of cervical intraepithelial neoplasia grades 2 or 3 in HIV-infected women treated by large loop excision of the transformation zone (LLETZ).
|
Sao Paulo Med J
|
2008
|
0.83
|
|
70
|
Moderate prevalence of transmitted drug resistance mutations among antiretroviral-naive HIV-infected pregnant women in Rio de Janeiro, Brazil.
|
AIDS Res Hum Retroviruses
|
2013
|
0.83
|
|
71
|
HIV and noncommunicable diseases (NCDs) in Latin America: a call for an integrated and comprehensive response.
|
J Acquir Immune Defic Syndr
|
2014
|
0.82
|
|
72
|
Aging with HIV: a practical review.
|
Braz J Infect Dis
|
2013
|
0.82
|
|
73
|
Validity of the International HIV dementia scale in Brazil.
|
Arq Neuropsiquiatr
|
2013
|
0.82
|
|
74
|
AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000-2008: hospital-based cohort studies.
|
BMC Infect Dis
|
2014
|
0.80
|
|
75
|
Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects.
|
Vaccine
|
2012
|
0.80
|
|
76
|
Transgender People and HIV Prevention: What We Know and What We Need to Know, a Call to Action.
|
J Acquir Immune Defic Syndr
|
2016
|
0.80
|
|
77
|
H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses.
|
PLoS One
|
2012
|
0.79
|
|
78
|
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.
|
Clin Infect Dis
|
2013
|
0.79
|
|
79
|
Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected Pregnant Women and Adverse Infant Outcomes.
|
Pediatr Infect Dis J
|
2016
|
0.79
|
|
80
|
Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
|
Trials
|
2010
|
0.79
|
|
81
|
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study.
|
J Acquir Immune Defic Syndr
|
2015
|
0.79
|
|
82
|
Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial.
|
J Acquir Immune Defic Syndr
|
2016
|
0.79
|
|
83
|
Multi-state models for defining degrees of chronicity related to HIV-infected patient therapy adherence.
|
Cad Saude Publica
|
2013
|
0.78
|
|
84
|
Unprotected sex among men who have sex with men living with HIV in Brazil: a cross-sectional study in Rio de Janeiro.
|
BMC Public Health
|
2014
|
0.78
|
|
85
|
Evaluation of MCM-2 expression in TMA cervical specimens.
|
PLoS One
|
2012
|
0.78
|
|
86
|
Prevalence and risk factors associated with anal intraepithelial neoplasia among HIV-positive men in Brazil.
|
J Low Genit Tract Dis
|
2014
|
0.77
|
|
87
|
Adverse drug reactions associated with antiretroviral therapy during pregnancy.
|
Expert Opin Drug Saf
|
2014
|
0.77
|
|
88
|
[Performance by cytology and hybrid capture II in screening for high-grade squamous intraepithelial lesions in women with HIV].
|
Cad Saude Publica
|
2011
|
0.77
|
|
89
|
Neurological manifestations of coinfection with HIV and human T-lymphotropic virus type 1.
|
AIDS
|
2012
|
0.77
|
|
90
|
Outcomes of second-line combination antiretroviral therapy for HIV-infected patients: a cohort study from Rio de Janeiro, Brazil.
|
BMC Infect Dis
|
2014
|
0.77
|
|
91
|
Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.
|
HIV Clin Trials
|
2015
|
0.77
|
|
92
|
Short communication: neutralizing antibodies in HIV-1-infected Brazilian individuals.
|
AIDS Res Hum Retroviruses
|
2012
|
0.76
|
|
93
|
An evaluation of p16(INK4a) expression in cervical intraepithelial neoplasia specimens, including women with HIV-1.
|
Mem Inst Oswaldo Cruz
|
2012
|
0.76
|
|
94
|
Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS.
|
Braz J Infect Dis
|
2009
|
0.76
|
|
95
|
Authors' Reply: Is Genotype Testing Really Cost-Effective for Primary Resistance in Brazil?
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
96
|
Human immunodeficiency virus encephalopathy: cognitive and radiologic improvement after antiretroviral therapy.
|
Arch Neurol
|
2009
|
0.75
|
|
97
|
A Comparison of Hepatitis B Virus Infection in HIV-infected and HIV-uninfected Participants Enrolled in a Multi-National Clinical Trial: HPTN 052.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
98
|
First report of prevalence of HTLV-1 among HIV-1/2 infected children in Mozambique.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
99
|
Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections are associated with systemic CD8+ T cell activation.
|
AIDS
|
2017
|
0.75
|
|
100
|
Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
101
|
HIV-infected women in Europe: gender-specific needs and challenges.
|
Antivir Ther
|
2013
|
0.75
|
|
102
|
Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.
|
Mem Inst Oswaldo Cruz
|
2007
|
0.75
|
|
103
|
Unprotected sexual practices among men who have sex with women and men who have sex with men living with HIV/AIDS in Rio de Janeiro.
|
Arch Sex Behav
|
2014
|
0.75
|
|
104
|
30-day readmission rates in an HIV-infected cohort from Rio de Janeiro, Brazil.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
105
|
Recovery of Bone Mineral Density Following Discontinuation of Tenofovir-Based HIV Pre-Exposure Prophylaxis.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
106
|
Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
|
J Med Virol
|
2012
|
0.75
|